The present invention relates to a lactic acid bacterial fermentation promoter, containing at least one organic acid selected from malic acid and fumaric acid.

Provided are a breast milk-derived Lactobacillus plantarum and use thereof. The breast milk-derived Lactobacillus plantarum, which was screened from healthy breast milk, is classified and named as Lactobacillus plantarum and has an accession number of CGMCC NO.19748. It has strong adhesion, has an inhibitory effect on 8 commonly known pathogenic bacteria, and is susceptible to 8 antibiotics, and also has strong acid resistance and bile salt resistance.

The present invention provides a method of controlling growth of unwanted microorganisms by limiting their access to manganese. More specifically, the present invention provides a method of inhibiting or delaying growth of yeast and mold by reducing the manganese concentration in a product which is preferably a food product. The invention also provides manganese scavengers and uses thereof to inhibit or delay fungal growth.

The present invention provides novel use of Lactobacillus paracasei subsp. paracasei K56 in alleviation of intestinal inflammation. Lactobacillus paracasei subsp. paracasei K56 of the present invention has the deposit number CGMCC 15139 or DSM 27447. It was discovered in the present invention that the strain alone was highly efficacious at alleviating intestinal inflammation, reducing inflammatory factors IL-6 and/or TNF-α, promoting the anti-inflammatory factor IL-10, and reducing the tissue damage of colitis.

The present invention relates to the isolated strain of Lactobacillus plantarum VF46A deposited at the CNCM (Collection Nationale De Cultures de Microorganismes, INSTITUT PASTEUR, 25 rue du Docteur Roux, F-75724 PARIS CEDEX15) under the number CNCM 1-5301 on 29 Mar. 2018 as well as to a pharmaceutical composition, a food supplement and a food comprising said strain.

A composition for promoting development of the intestinal tract, a composition for improving lung function or a composition for improving immune function containing a bacterium belonging to Bifidobacterium longum subsp. infantis is provided. The bacterium is preferably Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623).

Disclosed are a yoghurt for regulating intestinal tract, preparation method therefor, and use thereof, where the yogurt is prepared from raw materials comprising the following parts by weight: 90-97 parts of raw milk, Lactobacillus gasseri of (0.7-5)×10.sup.8 CFU/100 g raw milk, Streptococcus thermophilus of (0.1-9)×10.sup.10 CFU/100 g raw milk, Lactobacillus bulgaricus of (0.1-9)×10.sup.10 CFU/100 g raw milk, Lactobacillus acidophilus of (0.5-7)×10.sup.8 CFU/100 g raw milk, Lactobacillus plantarum of (0.5-7)×10.sup.8 CFU/100 g raw milk, Lactobacillus paracasei of (0.1-9)×10.sup.7 CFU/100 g raw milk, and other probiotics, and prebiotics such as inulin. The yogurt may regulate the balance of intestinal flora and prevent constipation and gestational diabetes in overweight and/or obese pregnant women during the gestation period.

The present invention provides novel use of Bifidobacterium lactis BL-99 in suppression of intestinal inflammation. Bifidobacterium lactis BL-99 of the present invention has the deposit number CGMCC 15650. It was discovered in the present invention that the strain alone was highly efficacious at suppressing intestinal inflammation, reducing inflammatory factors IL-6 and/or TNF-α, promoting anti-inflammatory factor IL-10, and reducing the tissue damage of colitis.

The present invention provides novel Lactococcus lactis lactic acid bacterium strains having improved texturing properties and methods of using the strains for producing food products.

A synergistic combination of butyric-acid-producing prebiotics and probiotics, which is used in the fields of foods, dietary supplements and drugs. Specifically, a composition containing probiotics and prebiotics, a food, dietary supplement or pharmaceutical preparation including the composition, and the use of the composition for alleviating and improving a disease or a discomfort, or reducing the occurrence of a disease or a discomfort, wherein the disease or discomfort is related to insufficient butyric acid in the intestine, or to insufficient butyric-acid-producing microorganisms in the intestine. A method for promoting Bifidobacterium lactis HNO19 to produce butyric acid, the method including using a galactooligosaccharide and lactulose as carbon sources for the cultivation of Bifidobacterium lactis HNO19, wherein the weight ratio of the galactooligosaccharide to lactulose is 1:1 to 4:1.